Apparently a group of Japanese researchers determined a while ago that we need to know whether abiraterone acetate (Zytiga) or enzalutamide (Xtandi) is the better drug for first-line treatment of chemotherapy-naive patients with castration-resistant prostate cancer (CRPC) — whether it is metastatic or non-metastatic in type. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-resistant, enzalutamide, head-to head, trial | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 